How does biallelic inactivation of KEAP1/STK11 affect response to dual immune checkpoint blockade in #NSCLC? 🧬🫁

Find out from Mark Jeng (@mjeng21) who discusses findings from a study investigating gene zygosity and #immunotherapy 🧪

Watch:

#Oncology

Biallelic inactivation of KEAP1/STK11 predicts response to checkpoint blockade in NSCLC

Mark Jeng, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares insights into a study evaluating the r...

ow.ly

Could #AI accelerate cancer clinical research? 🤔

Jai Patel at #ASCO26 discusses how AI-driven trial matching could reduce burden on clinical research staff to improve screening numbers for cancer trials 🏥🖥️

Watch:

#Oncology #CCDR @ASCO

How can AI-driven trial matching accelerate cancer clinical research?

Jai Patel, PharmD, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, discusses the poten...

ow.ly

Watch our recent interview with Evan Garrad (@GarradEvan) at #WCLC26 to hear about implementation of the Sybil consortium, an open access machine learning model that assesses #LungCancer risk from low-dose CT scans 🖥️🔬

🔗

#LCSM #Oncology #OncoRad

Sybil implementation and social determinants of lung cancer risk prediction

Evan Garrad, MD, University of Illinois Chicago, Chicago, IL, discusses the implementation of the Sybil, an open acc...

ow.ly

What do the results from the A-BRAVE trial suggest about the effect of time-of-day administration on outcomes from adjuvant avelumab in high-risk early-stage #TNBC? 🕰️🤔

Find out from Shipra Gandhi (@gandhi_shipra) who discussed the findings with us at #ASCO26 📊

Watch:

📢 This #ThyroidCancer Awareness Month, stay up to date with evolving systemic treatment strategies. Nabil Saba discusses the latest ASCO guidelines, treatment sequencing in radioiodine-refractory differentiated thyroid cancer, and emerging approaches for aggressive subtypes.